PMID- 33732261
OWN - NLM
STAT- MEDLINE
DCOM- 20210401
LR  - 20231104
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 12
DP  - 2021
TI  - Association of HLA Class I Genotypes With Severity of Coronavirus Disease-19.
PG  - 641900
LID - 10.3389/fimmu.2021.641900 [doi]
LID - 641900
AB  - Human leukocyte antigen (HLA) class I molecules play a crucial role in the 
      development of a specific immune response to viral infections by presenting viral 
      peptides at the cell surface where they will be further recognized by T cells. In 
      the present manuscript, we explored whether HLA class I genotypes can be 
      associated with the critical course of Coronavirus Disease-19 by searching 
      possible connections between genotypes of deceased patients and their age at 
      death. HLA-A, HLA-B, and HLA-C genotypes of n = 111 deceased patients with 
      COVID-19 (Moscow, Russia) and n = 428 volunteers were identified with 
      next-generation sequencing. Deceased patients were split into two groups 
      according to age at the time of death: n = 26 adult patients aged below 60 and n 
      = 85 elderly patients over 60. With the use of HLA class I genotypes, we 
      developed a risk score (RS) which was associated with the ability to present 
      severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) peptides by the HLA 
      class I molecule set of an individual. The resulting RS was significantly higher 
      in the group of deceased adults compared to elderly adults [p = 0.00348, area 
      under the receiver operating characteristic curve (AUC ROC = 0.68)]. In 
      particular, presence of HLA-A(*)01:01 allele was associated with high risk, while 
      HLA-A(*)02:01 and HLA-A(*)03:01 mainly contributed to low risk. The analysis of 
      patients with homozygosity strongly highlighted these results: homozygosity by 
      HLA-A(*)01:01 accompanied early deaths, while only one HLA-A(*)02:01 homozygote 
      died before 60 years of age. Application of the constructed RS model to an 
      independent Spanish patients cohort (n = 45) revealed that the score was also 
      associated with the severity of the disease. The obtained results suggest the 
      important role of HLA class I peptide presentation in the development of a 
      specific immune response to COVID-19.
CI  - Copyright (c) 2021 Shkurnikov, Nersisyan, Jankevic, Galatenko, Gordeev, Vechorko 
      and Tonevitsky.
FAU - Shkurnikov, Maxim
AU  - Shkurnikov M
AD  - Faculty of Biology and Biotechnology, HSE University, Moscow, Russia.
FAU - Nersisyan, Stepan
AU  - Nersisyan S
AD  - Faculty of Biology and Biotechnology, HSE University, Moscow, Russia.
FAU - Jankevic, Tatjana
AU  - Jankevic T
AD  - Center for Precision Genome Editing and Genetic Technologies for Biomedicine, 
      Pirogov Russian National Research Medical University, Moscow, Russia.
FAU - Galatenko, Alexei
AU  - Galatenko A
AD  - Faculty of Biology and Biotechnology, HSE University, Moscow, Russia.
AD  - Faculty of Mechanics and Mathematics, Lomonosov Moscow State University, Moscow, 
      Russia.
FAU - Gordeev, Ivan
AU  - Gordeev I
AD  - Center for Precision Genome Editing and Genetic Technologies for Biomedicine, 
      Pirogov Russian National Research Medical University, Moscow, Russia.
AD  - O.M. Filatov City Clinical Hospital, Moscow, Russia.
FAU - Vechorko, Valery
AU  - Vechorko V
AD  - O.M. Filatov City Clinical Hospital, Moscow, Russia.
FAU - Tonevitsky, Alexander
AU  - Tonevitsky A
AD  - Faculty of Biology and Biotechnology, HSE University, Moscow, Russia.
AD  - Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of 
      Sciences, Moscow, Russia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210223
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (HLA-A Antigens)
SB  - IM
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Alleles
MH  - COVID-19/*immunology/*mortality/pathology/virology
MH  - Cohort Studies
MH  - Female
MH  - Gene Frequency
MH  - Genetic Testing/methods
MH  - *Genotype
MH  - HLA-A Antigens/*genetics
MH  - High-Throughput Nucleotide Sequencing/methods
MH  - Homozygote
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - SARS-CoV-2/*genetics
MH  - *Severity of Illness Index
PMC - PMC7959787
OTO - NOTNLM
OT  - COVID-19
OT  - HLA class I
OT  - MHC class I
OT  - SARS-CoV-2
OT  - peptide presentation
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/03/19 06:00
MHDA- 2021/04/02 06:00
PMCR- 2021/02/23
CRDT- 2021/03/18 06:47
PHST- 2020/12/15 00:00 [received]
PHST- 2021/02/02 00:00 [accepted]
PHST- 2021/03/18 06:47 [entrez]
PHST- 2021/03/19 06:00 [pubmed]
PHST- 2021/04/02 06:00 [medline]
PHST- 2021/02/23 00:00 [pmc-release]
AID - 10.3389/fimmu.2021.641900 [doi]
PST - epublish
SO  - Front Immunol. 2021 Feb 23;12:641900. doi: 10.3389/fimmu.2021.641900. eCollection 
      2021.